A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor

Human Gene Therapy

Volumn 8, Issue 1, 1997, Pages

  Dranoff, G ^a   Soiffer, R ^a   Lynch, T ^a   Mihm, M ^a   Jung, K ^a   Kolesar, K ^a   Liebster, L ^a   Lam, P ^a   Duda, R ^a   Mentzer, S ^a   Singer, S ^a   Tanabe, K ^a   Johnson, R ^a   Sober, A ^a   Bhan, A ^a   Clift, S ^a   Cohen, L ^a   Parry, G ^a   Rokovich, J ^a   Richards, L ^a   Drayer, J ^a   Berns, A ^a   Mulligan, R C ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

AUTOTRANSPLANTATION; CANCER IMMUNOTHERAPY; CELL TRANSPLANTATION; CLINICAL PROTOCOL; CLINICAL TRIAL; GENE THERAPY; GENETIC ENGINEERING; HUMAN; MELANOMA; MELANOMA CELL; PHASE 1 CLINICAL TRIAL; REVIEW; VACCINATION;

EID: 16944364126     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1997.8.1-111     Document Type: Review

References (61)

1. Boring C, Squires T, Tong T, et al. Cancer Statistics. CA 1994;44:7-26.
2. Koh H. Cutaneous melanoma. N. Engl. J. Med. 1991;325:171-182.
3. Balch C, Houghton AN, Peters LJ. Cutaneous Melanoma. In: Vincent T. DeVita J, Hellman S, Rosenberg SA, ed. Cancer: Principles and Practice of Oncology. Fourth ed. Philadelphia: J. B. Lippincott Co, 1993:1612-1661.
4. Lienard D, Ewelenko P, Delmotte J, et al. High dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 1992;10:52-60.
5. Cocconi G, Bella M, Calabresi F, et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N. Engl. J. Med. 1992;327:516-523.
6. Penn I. Cancer in immunosuppressed patients. Transpl. Proc. 1984;16:492-494.
7. Nathanson L. Spontaneous regression of malignant melanoma: A review of the literature on incidence, clinical features, and possible mechanisms. Natl. Cancer Inst. Monogr. 1976;44:67-76.
8. Ferradini L, Mackensen A, Genevee C, et al. Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. J. Clin. Invest. 1993;91:1183-1190.
9. Mackensen A, Ferradini L, Carcelain G, et al. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res. 1993;53:3569-3573.
10. Mackensen A, Carcelain G, Viel S, et al. Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J. Clin. Invest. 1994;93:1397-1402.
11. Darrow TL, Slingluff CL, Siegler HF. Autologous lymph node cell-derived tumor-specific cytotoxic T-cells for use in adoptive immunotherapy of human melanoma. Cancer 1988;62:84-91.
12. Coulie PG, Somville M, Lehmann F, et al. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int. J. Cancer 1992;50:289-297.
13. Herin M, Lemoine C, Weynants P, et al. Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int. J. Cancer 1987;39:390-396.
14. Itoh K, Platsoucas CD, Balch CM. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin-2 and autologous tumor cells, and involvement of the T cell receptor. J. Exp. Med. 1988;168:1419-1441.
15. Knuth A, Danowski B, Oettgen HF, Old L. T-cell mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin-2-dependent T cell cultures. Proc. Natl. Acad. Sci. U.S.A. 1984;81:3511-3515.
16. Mukherji B, MacAlister TJ. Clonal analysis of cytotoxic T cell response against human melanoma. J. Exp. Med. 1983;158:240-245.
17. Wolfel T, Klehmann E, Muller C, Schutt K-H, Buschenfelde K-H, Knuth A. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J. Exp. Med. 1989;170:797-810.
18. De Vries JE, Spits H. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. J. Immunol. 1984;132:510-519.
19. Fossati G, Taramelli D, Balsari A, Bogdanovich G, Andreola S, Parmiani G. Primary but not metastatic human melanomas expressing DR antigens stimulate autologous lymphocytes. Int. J. Cancer 1984;33:591-597.
20. Slingluff CL, Cox Al, Henderson RA, Hunt DF, Engelhard VH. Recognition of human melanoma cells by HLA-A2.1 restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes. J. Immunol. 1993;150:2955-2963.
21. Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA. Shared human melanoma antigens. Recognition by tumor infiltrating lymphocytes in HLA-A2.1 transfected melanomas. J. Immunol. 1992;148:638-643.
22. Viret C, Davodeau F, Guilloux Y, et al. Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes. Eur. J. Immunol. 1993;23:141-146.
23. Anichini A, Maccalli C, Mortarini R, et al. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J. Exp. Med. 1993;177:989-998.
24. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 1993;178:489-495.
25. Traversari C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 1992;176:1453-1457.
26. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-1647.
27. Wolfel T, Van Pel A, Brichard V, et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 1994;24:759-764.
28. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. U.S.A. 1994;91:6458-6462.
29. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. U.S.A. 1994;91:3515-3519.
30. Houghton AN, Mintzer D, Cordon-Cardo C, et al. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. U.S.A. 1985;82:1242-1246.
31. Houghton AN, Chapman PB, Bajorin DF. Melanoma: Antibodies in Cancer Therapy. In: Vincent T. DeVita J, Hellman S, Rosenberg SA, ed. Biologic Therapy of Cancer. Philadelphia: J. B. Lippincott, 1991:533-549.
32. Irie RF, Morton DL. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc. Natl. Acad. Sci. U.S.A. 1986;83:8694-8698.
33. Livingston PO, Natoli EJ, Calves MJ, Stockert E, Oettgen HF, Old LJ. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc. Natl. Acad. Sci. U.S.A. 1987;84:2911-2915.
34. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-iodiotype monoclonal antibody MK2-23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc. Natl. Acad. Sci. U.S.A. 1992;89:466-470.
35. Kirkwood JM, Ernstoff MS. Cutaneous Melanoma: Interferons-Clinical Applications. In: Vincent T. DeVita J, Hellman S, Rosenberg SA, ed. Biologic Therapy of Cancer. Philadelphia: J. B. Lippincott, 1991: 311-333.
36. Alexander RB, Rosenberg SA. Tumor Necrosis Factor: Clinical Applications. In: Vincent T. DeVita J, Hellman S, Rosenberg SA, ed. Biologic Therapy of Cancer. Philadelphia: J. B. Lippincott, 1991:378-392.
37. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N. Engl. J. Med. 1987;316:889-897.
38. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 1993;85:622-632.
39. Rosenberg SA, Packard B. Aebersold P, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 1988;319:1676-1680.
40. Schwartzentruber DJ, Hom SS, Dadmarz R, et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J. Clin. Oncol. 1994;12:1475-1483.
41. Oettgen HF, Livingston PO, Old LJ. Melanoma: Immunotherapy by Active Specific Immunization. In: Vincent T. DeVita J, Hellman S, Rosenberg SA, ed. Biologic Therapy of Cancer. Philadelphia: J. B. Lippincott, 1991: 682-702.
42. Barth A, Hoon DSB, Foshag LJ, et al. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res. 1994;54:3342-3345.
43. Berd D, Murphy G, Maguire HC, Matrangelo MJ. Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res. 1991;51:2731-2734.
44. Hersey P. Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma. World J. Surg. 1992;16:251-260.
45. Mitchell MS, Harel W, Kempf RA, et al. Active-specific immunotherapy for melanoma. J. Clin. Oncol. 1990;8:856-869.
46. Morton DL, Foshag LJ, Hoon DSB, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 1992;216: 463-482.
47. Dranoff G, Mulligan RC. Gene transfer as cancer therapy. Adv. Immunol. 1994;In press.
48. Aoki T, Tashiro K, Miyatake S-I, et al. Expression of murine interleukin-7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc. Natl. Acad. Sci. U.S.A. 1992;89:3850-3854.
49. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397-403.
50. Gansbacher B, Zier K, Daniels B, Kronin K, Bannerji R, Gilboa E. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 1990;172:1217-1224.
51. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 1990;50:7820-7825.
52. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-716.
53. Porgador A, Tzehoval E, Katz A, et al. Interleukin-6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 1992;52:3679-3686.
54. Watanabe Y, Kuribayashi K, Miyatake S, et al. Exogenous expression of mouse interferon γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented antitumor immunity. Proc. Natl. Acad. Sci. U.S.A. 1989;86: 9456-9460.
55. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 1993; 90:3539-3543.
56. Saito S, Bannerji R, Gansbacher B, et al. Immunotherapy of bladder, cancer with cytokine gene-modified tumor vaccines. Cancer Res. 1994;54:3516-3520.
57. Sanda MG, Ayyagari SR, Jaffee EM, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol. 1994;151:622-628.
58. Jaffee EM, Dranoff G, Cohen LK, et al. High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res. 1993;53:2221-2226.
59. Berd D, Maguire HC, McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J. Clin. Oncol. 1990;8:1858-1867.
60. McCune CS, O'Donnell RW, Marquis DM, Sahasrabudhe DM. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol. Immunother. 1990; 32;62-66.
61. Kaplan G, Walsh G, Guido L, et al. Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J. Exp. Med. 1992;175:1717-1728.